Incidence of new fractures in older patients with osteoporosis receiving biosimilar teriparatide or reference products: A retrospective cohort study.

So SatoYusuke SasabuchiAkira OkadaHideo Yasunaga

Published in: British journal of clinical pharmacology (2024)

The biosimilar teriparatide showed effectiveness and safety comparable with those of the reference products in treating osteoporosis patients. Our results suggest that clinicians need not hesitate to prescribe biosimilar teriparatide for osteoporosis patients.

Keyphrases

bone mineral density
end stage renal disease
postmenopausal women
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
palliative care
risk factors